Who we are
About EMRIS pharma
Our mission is to revolutionize cancer treatment by preventing skin toxicities associated with targeted therapies, improving patients’ quality of life and compliance.
We are driven by a commitment to innovation, collaboration, and making a real impact in the world of healthcare.
Unmet Need
Targeted cancer therapies cause significant side effects. Most Patients (80%-90%) treated with EGFR inhibitor (EGFRi) monoclonal antibodies for advanced colon, head and neck, and lung cancers, suffer from skin toxicities that severely impair their quality of life and lead to non-adherence to the anti-cancer treatment.
Current treatments for these skin toxicities have limited benefits and include skin moisturizers, sunscreens, topical steroids, and antibiotics. Unfortunately, the most effective treatment is dose reduction or discontinuation of the anti-cancer drug.
90% of patients suffer from skin toxicities
Our Breakthrough Solution
We propose a first-in-class topical solution to prevent the toxicity by blocking the anti cancer drug in skin.
Our solution can effectively improve patients’ quality of life with no interference with the cancer treatment.
By topically blocking the drug only at the toxicity site, we aim to optimize therapy and potentially improve patient outcomes.
Intellectual Property
PCT Patent Application for skin toxicity prevention and drug delivery (filed Aug. 2020)
Publication
Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions
